PIK3CD and B-cell chronic lymphocytic leukemia: Idelalisib is a PI3K-δ inhibitor, more specifically p110δ a primary PI3K isoform in B cells and has shown activity in lymphoid malignancies and been FDA-approved for relapsed chronic lymphocytic leukaemia (CLL), follicular lymphoma and small lymphocytic lymphoma (Ref.